Fjarde Ap-fonden’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$73.9M Sell
148,682
-1,280
-0.9% -$567K 0.35% 55
2026
Q1
$67M Buy
149,962
+60,900
+68% +$28.4M 0.37% 52
2025
Q4
$40.4M Sell
89,062
-560
-0.6% -$241K 0.34% 62
2025
Q3
$35.1M Sell
89,622
-1,466
-2% -$613K 0.3% 69
2025
Q2
$40.6M Buy
91,088
+17,200
+23% +$7.93M 0.37% 53
2025
Q1
$35.8M Buy
73,888
+5,800
+9% +$2.7M 0.43% 43
2024
Q4
$27.4M Sell
68,088
-3,900
-5% -$1.81M 0.28% 67
2024
Q3
$33.5M Buy
+71,988
New +$34.6M 0.34% 52
2024
Q1
$29.7M Buy
70,988
+2,000
+3% +$845K 0.33% 57
2023
Q4
$28.1M Sell
68,988
-2,500
-3% -$924K 0.35% 51
2023
Q3
$24.9M Sell
71,488
-1,200
-2% -$420K 0.33% 55
2023
Q2
$25.6M Buy
72,688
+6,700
+10% +$2.26M 0.31% 59
2023
Q1
$20.8M Sell
65,988
-900
-1% -$270K 0.28% 79
2022
Q4
$19.3M Sell
66,888
-34,898
-34% -$10.6M 0.27% 81
2022
Q3
$28.7M Hold
101,786
0.36% 54
2022
Q2
$28.7M Buy
101,786
+31,700
+45% +$8.48M 0.36% 54
2022
Q1
$18.3M Sell
70,086
-401
-0.6% -$95.2K 0.18% 109
2021
Q4
$15.5M Sell
70,487
-700
-1% -$136K 0.14% 142
2021
Q3
$12.9M Sell
71,187
-548
-0.8% -$107K 0.12% 164
2021
Q2
$14.5M Sell
71,735
-5,600
-7% -$1.17M 0.13% 153
2021
Q1
$16.6M Buy
77,335
+300
+0.4% +$65.9K 0.15% 134
2020
Q4
$18.2M Sell
77,035
-2,300
-3% -$528K 0.17% 120
2020
Q3
$21.6M Buy
79,335
+5,300
+7% +$1.46M 0.24% 84
2020
Q2
$21.5M Buy
74,035
+4,342
+6% +$1.18M 0.27% 72
2020
Q1
$16.6M Sell
69,693
-300
-0.4% -$68.8K 0.27% 74
2019
Q4
$15.3M Buy
69,993
+4,400
+7% +$890K 0.19% 115
2019
Q3
$11.1M Buy
65,593
+1,400
+2% +$248K 0.14% 164
2019
Q2
$11.8M Sell
64,193
-7,500
-10% -$1.31M 0.15% 151
2019
Q1
$13.2M Buy
71,693
+12,033
+20% +$2.22M 0.17% 127
2018
Q4
$9.89M Sell
59,660
-7,700
-11% -$1.33M 0.17% 124
2018
Q3
$13M Sell
67,360
-2,902
-4% -$517K 0.19% 115
2018
Q2
$11.9M Buy
70,262
+254
+0.4% +$39.4K 0.18% 123
2018
Q1
$11.4M Buy
70,008
+744
+1% +$122K 0.17% 129
2017
Q4
$10.4M Buy
69,264
+10,892
+19% +$1.61M 0.16% 142
2017
Q3
$8.88M Buy
58,372
+1,122
+2% +$169K 0.17% 135
2017
Q2
$7.38M Buy
57,250
+6,788
+13% +$817K 0.15% 153
2017
Q1
$5.52M Sell
50,462
-2,962
-6% -$261K 0.13% 173
2016
Q4
$3.94M Sell
53,424
-5,445
-9% -$443K 0.09% 248
2016
Q3
$5.13M Buy
58,869
+1,508
+3% +$143K 0.11% 210
2016
Q2
$4.93M Buy
57,361
+1,438
+3% +$124K 0.11% 206
2016
Q1
$4.45M Buy
55,923
+7,338
+15% +$664K 0.1% 221
2015
Q4
$6.11M Buy
48,585
+1,127
+2% +$136K 0.16% 143
2015
Q3
$4.94M Sell
47,458
-3,459
-7% -$444K 0.14% 171
2015
Q2
$6.29M Sell
50,917
-3,267
-6% -$412K 0.15% 156
2015
Q1
$6.39M Sell
54,184
-2,204
-4% -$264K 0.15% 163
2014
Q4
$6.7M Sell
56,388
-4,606
-8% -$519K 0.15% 163
2014
Q3
$6.85M Sell
60,994
-5,223
-8% -$497K 0.15% 156
2014
Q2
$6.27M Sell
66,217
-1,138
-2% -$79.8K 0.12% 184
2014
Q1
$4.76M Buy
67,355
+2,396
+4% +$190K 0.09% 242
2013
Q4
$4.83M Sell
64,959
-404
-0.6% -$28.1K 0.1% 221
2013
Q3
$4.96M Sell
65,363
-19,014
-23% -$1.51M 0.11% 215
2013
Q2
$6.74M Buy
+84,377
New +$6.21M 0.14% 159

Other funds holding VRTX

Fjarde Ap-fonden's VRTX Position: Q2 2026 in Review

Fjarde Ap-fonden reduced its Vertex Pharmaceuticals (VRTX) stake by 0.85% in Q2 2026, selling an estimated $567K and leaving 148,682 shares worth $73.9M. The position accounts for 0.35% of the portfolio, ranked #55.

Fjarde Ap-fonden first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Fjarde Ap-fonden held 148,682 shares of Vertex Pharmaceuticals worth $73.9M as of Q2 2026.
  • Fjarde Ap-fonden sold 1,280 Vertex Pharmaceuticals shares in Q2 2026, an estimated $567K.
  • Vertex Pharmaceuticals made up 0.35% of Fjarde Ap-fonden's portfolio in Q2 2026, its #55 holding.
  • Fjarde Ap-fonden first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Fjarde Ap-fonden's 13F filing for Q2 2026, filed 29 Jul 2026.